$1.30
+0.13 (+11.11%)
Open$1.21
Previous Close$1.17
Day High$1.31
Day Low$1.21
52W High$13.48
52W Low$8.55
Volume—
Avg Volume517.6K
Market Cap37.49M
P/E Ratio16.16
EPS$0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+855.4% upside
Current
$1.30
$1.30
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.07M | 10.25M | 10.35M |
| Net Income | 2.46M | 2.27M | 1.98M |
| Profit Margin | 22.2% | 22.1% | 19.1% |
| EBITDA | 3.48M | 3.06M | 3.48M |
| Free Cash Flow | 1.46M | 1.07M | 1.08M |
| Rev Growth | +5.9% | +24.9% | +1.9% |
| Debt/Equity | 0.86 | 0.86 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |